

BRITISH JOURNAL OF PHARMACOLOGY

The *British Journal of Pharmacology* welcomes contributions in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

Edited for the British Pharmacological Society by

A.T. Birmingham
(Chairman)

R.W. Horton W.A. Large
(Secretaries)

Editorial Board

P.I. Aaronson <i>London</i>	Sheila M. Gardiner <i>Nottingham</i>	G. Martin <i>Beckenham</i>
C.J. Bailey <i>Birmingham</i>	C.J. Garland <i>Bristol</i>	A. Mathie <i>London</i>
L. Belardinelli <i>Gainesville, USA</i>	A. Gibson <i>London</i>	P.K. Moore <i>London</i>
Maria G. Belvisi <i>London</i>	M.A. Gienbycz <i>London</i>	H. Nilsson <i>Aarhus, Denmark</i>
G.W. Bennett <i>Nottingham</i>	W.R. Giles <i>Calgary, Canada</i>	H. Osswald <i>Tübingen, Germany</i>
T.P. Blackburn <i>Harlow</i>	R.G. Goldie <i>Perth, Australia</i>	F.L. Pearce <i>London</i>
M.R. Boarder <i>Leicester</i>	R.J. Griffiths <i>Groton, USA</i>	J.D. Pearson <i>London</i>
N.G. Bowery <i>Birmingham</i>	R.W. Gristwood <i>Cambridge</i>	U. Quast <i>Tübingen, Germany</i>
W.C. Bowman <i>Glasgow</i>	Judith M. Hall <i>Guildford</i>	A.G. Ramage <i>London</i>
R. Busse <i>Frankfurt, Germany</i>	D.W.P. Hay <i>Philadelphia, USA</i>	P.J. Roberts <i>Bristol</i>
S.P. Butcher <i>Edinburgh</i>	D.J. Heal <i>Nottingham</i>	W.C. Sessa <i>New Haven, USA</i>
K.D. Butler <i>Horsham</i>	P.G. Hellewell <i>London</i>	N. Shankley <i>London</i>
M. Caulfield <i>Dundee</i>	K. Hillier <i>Southampton</i>	N.L. Simmons <i>Newcastle</i>
R.A.J. Challiss <i>Leicester</i>	P. Holzer <i>Graz, Austria</i>	P.G. Skett <i>Glasgow</i>
R. Chess-Williams <i>Sheffield</i>	S.M.O. Hourani <i>Guildford</i>	P. Sneddon <i>Glasgow</i>
T. Cocks <i>Melbourne, Australia</i>	D. Hoyer <i>Basle, Switzerland</i>	S. Clare Stanford <i>London</i>
Helen M. Cox <i>London</i>	G.W. John <i>Castres, France</i>	K. Starke <i>Freiburg, Germany</i>
V. Crunelli <i>Cardiff</i>	E.J. Johns <i>Birmingham</i>	R.J. Summers <i>Melbourne, Australia</i>
A. Dickenson <i>London</i>	R.S.G. Jones <i>Oxford</i>	J. Tamargo <i>Madrid, Spain</i>
J.R. Docherty <i>Dublin</i>	P.A.T. Kelly <i>Edinburgh</i>	C. Thiemermann <i>London</i>
L. Edvinsson <i>Lund, Sweden</i>	D.A. Kendall <i>Nottingham</i>	M.D. Tricklebank <i>Basle, Switzerland</i>
G. Edwards <i>Manchester</i>	C. Kennedy <i>Glasgow</i>	T.J. Verbeuren <i>Suresnes, France</i>
R.M. Eglen <i>Palo Alto, USA</i>	I. Kitchen <i>Guildford</i>	R.R. Vollmer <i>Pittsburgh, USA</i>
P.C. Emson <i>Cambridge</i>	N.R. Kitteringham <i>Liverpool</i>	Cherry L. Wainwright <i>Glasgow</i>
R.H. Evans <i>Bristol</i>	R.Z. Kozlowski <i>Oxford</i>	T.D. Warner <i>London</i>
A.W. Ford-Hutchinson <i>Quebec, Canada</i>	S. Lazareno <i>London</i>	K.J. Watling <i>Boston, USA</i>
A.C. Foster <i>San Diego, USA</i>	R.A.J. Lefebvre <i>Ghent, Belgium</i>	J. Westwick <i>Bath</i>
J.R. Fozard <i>Basle, Switzerland</i>	J. Llenas <i>Barcelona, Spain</i>	K.I. Williams <i>Bath</i>
B.B. Fredholm <i>Stockholm, Sweden</i>	A.T. McKnight <i>Cambridge</i>	V.G. Wilson <i>Nottingham</i>
Allison D. Fryer <i>Baltimore, USA</i>	C.A. Maggi <i>Florence, Italy</i>	E.H.F. Wong <i>Milan, Italy</i>
J.P. Gallagher <i>Galveston, USA</i>	I.G. Marshall <i>Glasgow</i>	S. Wonnacott <i>Bath</i>
	Janice M. Marshall <i>Birmingham</i>	B. Woodward <i>Bath</i>

Corresponding Editors

P.R. Adams <i>Stony Brook, U.S.A.</i>	R.J. Miller <i>Chicago, U.S.A.</i>	L. Szekeres <i>Szeged, Hungary</i>
C. Bell <i>Dublin</i>	R.C. Murphy <i>Denver, U.S.A.</i>	B. Uvnas <i>Stockholm, Sweden</i>
F.E. Bloom <i>La Jolla, U.S.A.</i>	E. Muscholl <i>Mainz, Germany</i>	P.A. Van Zwieten <i>Amsterdam, Netherlands</i>
A.L.A. Boura <i>Newcastle, Australia</i>	R.A. North <i>Geneva, Switzerland</i>	V.M. Varagić <i>Belgrade, Yugoslavia</i>
N.J. Dun <i>Toledo, U.S.A.</i>	M. Otsuka <i>Tokyo, Japan</i>	G. Velo <i>Verona, Italy</i>
R.F. Furchgott <i>New York, U.S.A.</i>	M.J. Rand <i>Melbourne, Australia</i>	Wang Zhen Gang <i>Beijing, China</i>
T. Godfraind <i>Brussels, Belgium</i>	S. Rosell <i>Södertälje, Sweden</i>	M.B.H. Youdim <i>Haifa, Israel</i>
S.Z. Langer <i>Paris, France</i>	P. Seeman <i>Toronto, Canada</i>	

Submission of manuscripts: Manuscripts (two copies) should be sent to The Editorial Office, British Journal of Pharmacology, St. George's Hospital Medical School, Cranmer Terrace, London SW17 0RE.

Authors should consult the Instructions to Authors and the Nomenclature Guidelines for Authors in Vol. 117, 389–399. These Instructions and Guidelines also appear with the journal Index for Volumes 114–116, 1995. A checklist of the essential requirements is summarised in each issue of the journal, or as the last page of the issue.

Whilst every effort is made by the publishers and editorial committee to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they and the *British Pharmacological Society* wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the *British Pharmacological Society*, the publishers and the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement.

• Introduction: **G. de GATEANO** (Italy) - **W. BODE** (Germany) - Structure of human thrombin: a guide for selective inhibition • **R. CARRELL** (U.K) - Thrombin inhibition by the heparin-antithrombin complex • **A. T. NURDEN** (France) - Function of platelet membrane glycoproteins and its regulation • **M. L. OGLETREE** (USA) - Development of thromboxane receptor antagonists • **P. CARMELIET** (Belgium) - Targeted gene manipulation of the fibrinolytic and coagulation system • **P.-G. STEG** (France) - Restenosis after angioplasty: mechanisms and prevention. Is gene therapy a realistic approach? • **P. NAWROTH** (Germany) - Tissue factor - a target for gene therapy • **D. W. BANNER** (Switzerland) - Crystal structure of the factor VIIa/tissue factor complex: a basis for inhibitor design • **A. M. HENNEY** (UK) - Matrix metalloproteinases and vascular matrix remodelling: new candidate genes to consider in atherosclerosis? • **G. A. FITZGERALD** (USA) - Aspirin, past and present trials. Is there a future for a better aspirin? • **B. BONEU** (France) - Hirudin: clinical experience • **J.-M. HERBERT** (France) - An update on Ticlopidine and Clopidogrel as antiplatelet drugs • **G. MONTALESCOT** (France) - Management of acute coronary syndromes with antithrombotic drugs.

English will be used by the speakers

ANTITHROMBOTIC DRUGS: FROM CURRENT KNOWLEDGE AND THERAPEUTIC USES TO FUTURES AVENUES

March 6-7, 1997

Institut Pasteur, Paris, France.

Chairpersons: **Marie-Claude GUILLIN** (Hôpital Beaujon, France),
Jacques MACLOUF (INSERM U348, France) &
Beat Steiner (Hoffmann-La Roche, Switzerland).

December 4-6, 1996:

NEW TRENDS IN ATHEROSCLEROSIS RESEARCH

Institut Pasteur, Paris, France.

Chairpersons: **Jean-Charles Fruchart** (Institut Pasteur de Lille, France)
& **Patrice Denèfle** (Rhône Poulenc Rorer, France).



<http://www.pasteur.fr/Conf/euroconf.html>

For details

Return to: INSTITUT PASTEUR EUROCONFERENCES, 28 rue du Docteur Roux - 75015 - Paris - France or by fax (33-1) 40 61 34 05 - E-mail: ldrye@pasteur.fr

Name: Affiliation:

Address:

..... Post/Zip Code: City:

Country: Fax: Interested in conference:

The *British Journal of Pharmacology* is published by Stockton Press, a division of Macmillan Press Ltd. It is the official publication of the British Pharmacological Society.

Scope The *British Journal of Pharmacology* is published twice a month. It welcomes contributions in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

This journal is covered by Current Contents, Excerpta Medica, BIOSIS, CABS, CINAHL and Index Medicus.

Editorial Manuscripts (plus two copies) and all editorial correspondence should be sent to: The Editorial Office, *British Journal of Pharmacology*, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK. Tel: +44 (0)181 767 6765; Fax: +44 (0)181 767 5645.

Advertisements Enquiries concerning advertisements should be addressed to: Michael Rowley, Hasler House, High Street, Great Dunmow, Essex CM6 1AP, UK. Tel: +44 (0)1371 874613; Fax: +44 (0)1371 872273.

Publisher All business correspondence, supplement enquiries and reprint requests should be addressed to *British Journal of Pharmacology*, Stockton Press, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Tel: +44 (0)1256 29242; Fax: +44 (0)1256 810526. Publisher: Marija Vukovojac. Production Controller: Nicci Crawley. Supplement Production Controller: Simone Larché

Subscriptions - EU/Rest of World Subscription price per annum (3 volumes, 24 issues) £655, rest of world £735 (Surface mail) £880 (Airmail), or equivalent in any other currency. Orders must be accompanied by remittance. Cheques should be made payable to *Macmillan Magazines* and sent to: The Subscription Department, Macmillan Press Ltd, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Where appropriate, subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment. Subscribers from EC territories should add sales tax at the local rate.

Subscriptions - USA USA subscribers call toll free 1-800-221-2123 or send check/money order/credit card details to: Stockton Press, 345 Park Avenue South, 10th Floor, New York, NY 10010-1707; Tel: +1 212 689 9200, Fax: +1 212 689 9711. USA annual subscription rates (institutional/corporate): \$1170 (surface) \$1400 (airmail). Individual making personal payment: \$240.

British Journal of Pharmacology (ISSN 0007-1188) is published twice a month by Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel, NJ 07001, USA. Subscription price for institutions is \$1170 per annum (surface). 2nd class postage is paid at Rahway NJ. Postmaster: send address corrections to Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel NJ 07001.

Reprints of any article in this journal are available from Stockton Press, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Tel: +44 (0)1256 29242; Fax: +44 (0)1256 810526.

Copyright © 1996 Stockton Press
ISSN 0007-1188

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

All material published in this journal is protected by copyright, which covers exclusive rights to reproduce and distribute the material. No material published in this journal may be reproduced or stored on microfilm or in electronic, optical or magnetic form without the written authorisation of the Publisher.

Authorisation to photocopy items for internal or personal use of specific clients, is granted by Stockton Press for libraries and other users registered with the Copyright Clearance Center (CCC) Transaction Reporting Service, provided that the base fee of \$12.00 per copy is paid directly to CCC, 21 Congress St., Salem, MA 01970, USA. 0007-1188/96 \$12.00 + \$0.00.

Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patent Act 1988, this publication may be reproduced, stored or transmitted, in any form or by any means, only with the prior permission in writing of the publishers, or in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency.



STOCKTON
A Division of Macmillan Press

Fax:


STOCKTON

LIBRARY RECOMMENDATION FORM

To: Librarian/Library Acquisition Committee

I have just reviewed a sample copy of the journal detailed overleaf entitled:

Please include it in your next serials review meeting with my recommendation.

(Further sample copies are available from Stockton Press, Direct Marketing, Houndmills, Basingstoke Hampshire RG21 6XS, UK)

I recommend the journal for the following reasons:

Name: _____

Position: _____

Department: _____

LIBRARY RECOMMENDATION FORM

To: Librarian/Library Acquisition Committee

I have just reviewed a sample copy of the journal detailed overleaf entitled:

Please include it in your next serials review meeting with my recommendation.

(Further sample copies are available from Stockton Press, Journals Marketing, 345 Park Avenue South, 10th Floor, NY 10010-1707. USA)

I recommend the journal for the following reasons:

Name: _____

Position: _____

Department: _____

PREPARATION OF MANUSCRIPTS

Authors are strongly recommended to read the full *Instructions to Authors* and *Nomenclature Guidelines for Authors* (*Br. J. Pharmacol.* 1996, **117**, 389–399) before submitting a manuscript for publication in the *British Journal of Pharmacology*. The manuscript and cover letter should be checked against the following list before mailing.

The original and one copy of the manuscript must be supplied. Manuscripts must be typed in double-line spacing on one side of A4 paper, in type not smaller than 12 characters per inch or 10 point. Both copies to include Tables and a set of labelled Figures. One set of Figures without numbers or letters is also to be included. The text to be arranged in the following subsections:

1. **Title**—To have no more than 150 characters on a separate page, which should also include a Short Title (50 characters maximum) and the name and address of the author for correspondence.
2. **Summary**—To be arranged in numbered paragraphs (Full Papers) or a single paragraph (Special Reports).
—to include aims, principal results and conclusions.
—to include Key words (10 maximum) at end of summary.
3. **Introduction**—To contain concise statements of the problem and the aims of the investigation.
4. **Methods**—To have brief but adequate account of the procedures; *full names of drugs (including those referred to by manufacturer's code)*, sources of drugs and statistical tests to be stated.
5. **Results**—To have no repetition of data in Figures, Tables and text.
6. **Discussion**—Findings and conclusions to be placed in context of other relevant work.
NB Simple repetition of results and unwarranted speculation are not acceptable.
7. **Acknowledgements**—Sources of support. Sources of drugs not widely available commercially.
8. **References**—All references in the text to be included in the Reference List and *vice versa*. References in alphabetical order with complete citations; Journals publishing 'in press' papers identified.

References to manuscripts submitted to other journals but not yet accepted are not allowed.

9. **Tables**—Each on a separate page and prepared in accordance with current requirements of the Journal.
10. **Figures**—Both labelled and non-labelled Figures to be prepared in accordance with current requirements of the Journal (see *Instructions to Authors*, 1996, **117**, 389–396) and provided with Figure Number and Authors' names on back (*in pencil*).
—each legend to be typed on a separate page and carrying keys to symbols.
—keys to symbols and histograms must not appear on the figures themselves, but in the respective legends.
—'box style' figures are not in keeping with the Journal style; line drawings etc must have only left-hand and bottom axes.
11. **Manuscripts**—To be accompanied by a declaration signed by each author that
 - (a) results are original
 - (b) approval of all persons concerned has been given to submit manuscripts for consideration (see also 12b)
 - (c) the same material is neither 'in press' (i.e. is in proof or has definitely been accepted for publication) nor under consideration elsewhere. Furthermore it will not be submitted or published elsewhere before a decision has been reached by the Editorial Board of the *British Journal of Pharmacology* and will not be submitted elsewhere if accepted by the *British Journal of Pharmacology*.
 - (d) Copyright assignment is included.
12. **Cover letter**—To state clearly
 - (a) Corresponding author's full postal address, telephone, telex or Fax number
 - (b) where appropriate, that *either* ethical approval has been given for investigation *or* Company or Institutional permission to publish work has been received.
13. **Reminder**—Packaging to be sufficiently robust to protect Figures and to withstand mailing.

Failure to comply with *Instructions to Authors* may lead to substantial delays in processing, review and publication and may even jeopardize acceptance of the manuscript.

NOMENCLATURE

Authors are reminded that accepted receptor and associated terminology is laid out in *Nomenclature Guidelines for Authors*, as published in the *British Journal of Pharmacology*, *Br. J. Pharmacol.*, 1996, **117**, 397–399.

SPECIAL REPORTS

The purpose of *Special Reports* is to provide rapid publication for **new** and **important** results which the Editorial Board considers are likely to be of special pharmacological significance. *Special Reports* will have publication priority over all other material and so authors are asked to consider carefully the status of their work before submission.

In order to speed publication there is normally no revision allowed beyond very minor typographical or grammatical corrections. If significant revision is required, the Board may either invite rapid re-submission or, more probably, propose that it be re-written as a Full Paper and be re-submitted for consideration. In order to reduce delays, proofs of *Special Reports* will be sent to authors but **essential corrections must reach the Production Office within 48 hours of receipt**. Authors should ensure that their submitted material conforms exactly to the following requirements. **In a covering letter, the authors should state clearly and briefly, why THEY consider the Report to be of special pharmacological significance and should therefore receive priority for publication as a Special Report.**

Special Reports should normally occupy no more than two printed pages of the Journal; two illustrations (Figures or Tables, with legends) are permitted. As a guideline, with type face of 12 pitch and double-line spacing, a page of A4 paper could contain about 400 words. The absolute maximum length of the *Special Report* is 1700 words. For each Figure or Table, please deduct 200 words. The manuscript should comprise a Title page with key words (maximum of 10), a Summary consisting of a single short paragraph, followed by Introduction, Methods, Results, Discussion and References (maximum of 10). In all other respects, the requirements are the same as for Full Papers (see current 'Instructions to Authors').

PAPERS

- T. Az-ma, K. Fujii & O. Yuge.** Self-limiting enhancement by nitric oxide of oxygen free radical-induced endothelial cell injury: evidence against the dual action of NO as hydroxyl radical donor/scavenger **455**
- A.J. Hadley, M. Kumari, P.O. Cover, J. Osborne, R. Poyser, J.D. Flack & J.C. Buckingham.** Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by the type 4 phosphodiesterase (PDE-4) inhibitor, denbufylline **463**
- E. Delpy, H. Coste & A.-C. le Monnier de Gouville.** Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3 **471**
- H. Ruetten & C. Thiemermann.** Effect of selective blockade of endothelin ET_B receptors on the liver dysfunction and injury caused by endotoxaemia in the rat **479**
- H. Kankaanranta, M. Luomala, O. Kosonen & E. Moilanen.** Inhibition by fenamates of calcium influx and proliferation of human lymphocytes **487**
- K.M. Heygate, J. Davies, M. Holmes, R.F.L. James & H. Thurston.** The effect of insulin treatment and of islet transplantation on the resistance artery function in the STZ-induced diabetic rat **495**
- N. Satake, M. Shibata & S. Shibata.** The inhibitory effects of iberoxin and 4-aminopyridine on the relaxation induced by β_1 - and β_2 -adrenoceptor activation in rat aortic rings **505**
- E.A. Konorev, J. Joseph, M.M. Tarpey & B. Kalyanaraman.** The mechanism of cardioprotection by S-nitrosoglutathione monoethyl ester in rat isolated heart during cardioplegic ischaemic arrest **511**
- A.P. Albert, K.M. Spyer & P.A. Brooks.** The effect of 5-HT and selective 5-HT receptor agonists and antagonists on rat dorsal vagal preganglionic neurones *in vitro* **519**
- E. Southam, S.L. Charles & J. Garthwaite.** The nitric oxide-cyclic GMP pathway and synaptic plasticity in the rat superior cervical ganglion **527**
- M.P. Gorge, J.S. Hotherhall, G.H. Neild & A.A.N. Dutra.** Role of a copper (I)-dependent enzyme in the anti-platelet action of S-nitrosoglutathione **533**
- H. Sawai, R. Wang, T. Yamashita & S. Kokubun.** Effects of purinoceptor agonists on cytosolic Ca^{2+} concentration in swine tracheal smooth muscle cells in culture **539**
- B. Linck, P. Boknik, J. Knapp, F.U. Müller, J. Neumann, W. Schmitz & U. Vahlensieck.** Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts **545**
- F. Sierralta, D. Naquira, G. Pinardi & H.F. Miranda.** α -Adrenoceptor and opioid receptor modulation of clonidine-induced antinociception **551**
- T. Watano, J. Kimura, T. Morita & H. Nakanishi.** A novel antagonist, No. 7943, of the $\text{Na}^+/\text{Ca}^{2+}$ exchange current in guinea-pig cardiac ventricular cells **555**
- A.J. Hoey, C.M. Jackson, G.G. Pegg & M.N. Sillence.** Characteristics of cyanopindolol analogues active at the β_3 -adrenoceptor in rat ileum **564**
- M. Pfeiffer, A. Draguhn, H. Meierkord & U. Heinemann.** Effects of γ -aminobutyric acid (GABA) agonists and GABA uptake inhibitors on pharmacoresistant and pharmacoresistant epileptiform activity *in vitro* **569**
- M. Dikshit, S.S. Chari, P. Seth & R. Kumari.** Interaction of nitric oxide synthase inhibitors and their D-enantiomers with rat neutrophil luminol dependent chemiluminescence response **578**
- K. Kamata & T. Kobayashi.** Changes in superoxide dismutase mRNA expression by streptozotocin-induced diabetes **583**
- E. Fedele, Y. Jin, G. Varnier & M. Raiteri.** *In vivo* microdialysis study of a specific inhibitor of soluble guanylyl cyclase on the glutamate receptor/nitric oxide/cyclic GMP pathway **590**
- R.M. Eglén, B. Peelle, M.T. Pulido-Rios & E. Leung.** Functional interactions between muscarinic M₂ receptors and 5-hydroxytryptamine (5-HT)₄ receptors and β_3 -adrenoceptors in isolated oesophageal muscularis mucosae of the rat **595**
- K.A. Green, J.J. Lambert & G.A. Cottrell.** Ligand-gated ion channels opened by 5-HT in molluscan neurones **602**
- P.S. Pagel, D.A. Hettrick & D.C. Warltier.** Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs **609**